Isatuximab Plus VRd Wins EU Approval for Newly Diagnosed, Transplant-Ineligible Multiple Myeloma
The EMA’s CHMP has approved isatuximab in combination with VRd for transplant-ineligible patients with newly diagnosed multiple myeloma.
Related Articles
SHR-A1811 Maintains Efficacy, Safety in Pretreated HER2-Expressing/-Mutated Breast Cancer, Other Solid Tumors
An additional 1-year of follow-up confirmed the safety and activity of SHR-A1811 in HER2-expressing or -mutant solid tumors, including breast cancer.
IO-202 Plus Azacitidine Could Bring Long-Awaited Change in HMA-Naive CMML
Gabriel Mannis, MD, discusses the observed clinical activity and manageable safety profile of IO-202 combined with azacitidine in CMML.
A Closer Look at the 2024 NCCS State of Survivorship Survey : Oncology Times
An abstract is unavailable.
Quantitative IHC Assays May Bridge Gaps in Breast Cancer IHC Test Concordance
David Rimm, MD, PhD, discusses pathology limitations that have been exacerbated by the current lineup of breast cancer IHC tests.
Precision Medicine Heats Up Ahead of SOGO Annual Meeting in GI Cancer
E. Gabriela Chiorean, MD, FASCO, discusses exciting targeted therapies in the GI space and topics to be discussed at the School of Gastrointestinal Oncology meeting.
Registration
Prices are based on membership status. Once logged in, the correct registration rate will automatically populate. Registration Type Early Bird Price (October 7, 2024 –…
Selecting Among Guideline Recommended Treatment Options in Transplant-Eligible NDMM
Panelists discuss how to navigate and choose among multiple guideline-recommended induction regimens for patients with transplant-eligible newly diagnosed multiple myeloma (NDMM) by considering factors such…
FDA Grants Priority Review to RP1 Plus Nivolumab for Advanced Melanoma After Anti–PD-1 Therapy
The FDA granted priority review to the BLA for RP1 plus nivolumab in advanced melanoma following progression on an anti–PD-1 agent.
Bill Could Eliminate Cuts to Medicare Physician Reimbursement
“The cost of caring for a Medicare patient far outpaces the reimbursement that physicians receive for seeing them,” said Congressman Greg Murphy, MD (R-NC).
